Baijayanta Maiti is a Neurology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4921 Parkview Pl
Div Neurology Movement Disorders, 7th Fl
Saint Louis, MO 631101032
Telephone
314-362-6908Registry record last updated 17 Apr 2025.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
98%Neuromuscular Blocker97.9%Onabotulinumtoxina100%Part B, office-administered≥37 patientsgamma-Aminobutyric Acid-ergic Agonist0.1%Baclofen100%Part D<11 patientsNervous system
1.8%Aromatic Amino Acid Decarboxylation Inhibitor0.8%Carbidopa-Levodopa78%Carbidopa-Levodopa Er22%Part D≥55 patientsSSRI0.2%Trazodone Hcl57%Escitalopram Oxalate43%Part D≥12 patients+ 7 more classes in this area
Cardiovascular
0.1%alpha-Adrenergic Agonist0.1%Midodrine Hcl100%Part D<11 patientsBeta blocker0.1%Propranolol Hcl Er100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
- Cerebellar cholinergic connections as a biomarker of dementia and gait impairment in Parkinson disease
Washington University
FY2026$181,812K23NS125107 - Cerebellar cholinergic connections as a biomarker of dementia and gait impairment in Parkinson disease
Washington University
FY2025$182,520K23NS125107 - Cerebellar cholinergic connections as a biomarker of dementia and gait impairment in Parkinson disease
Washington University
FY2024$183,203K23NS125107
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”